Injective

Injective Protocol was founded by Eric Chen and Albert Chon.

Injective Protocol launched its mainnet in 2021, transitioning from a testnet to an operational mainnet.

Injective Protocol raised $3.6 million through an IEO at a price of $0.4 per INJ.

Injective uses a Tendermint Proof-of-Stake (PoS) consensus mechanism to secure its network while providing fast and efficient transaction processing. The chain's documentation cites a sustained throughput of about 25,000 transactions per second, with blocks roughly every 0.65 seconds. Injective's architecture is optimized for interoperability, with cross-chain capabilities allowing for easy interaction with various blockchains.

Injective offers several notable features:

• Interoperability: Provides cross-chain interactions that facilitate DeFi application deployment across ecosystems.
• Decentralized Finance (DeFi): Supports various financial products such as derivatives, spot trading, and lending within a decentralized framework.
• Zero Gas Fees: Offers gas-free transactions to enhance cost-effectiveness and accessibility.
• Governance: INJ token holders can participate in governance decisions, influencing protocol upgrades and changes.
• Composability: Makes it possible for easy integration and composability with other DeFi protocols and dApps.
• Security: Provides robust security through its PoS consensus, ensuring network resilience and integrity.

Despite its innovative features, Injective faces several challenges:

• Competition: Competes with other established DeFi platforms that offer similar functionalities.
• Adoption: Requires substantial user and developer adoption to leverage its full capabilities.
• Regulation: Must navigate a complex regulatory landscape that could impact its global expansion.
• Scalability: Injective cites a sustained capacity of about 25,000 TPS, but real-world performance must keep pace as on-chain trading activity grows.